{
    "clinical_study": {
        "@rank": "21728", 
        "arm_group": [
            {
                "arm_group_label": "Observational Arm", 
                "arm_group_type": "No Intervention"
            }, 
            {
                "arm_group_label": "Ivacaftor", 
                "arm_group_type": "Experimental", 
                "description": "Ivacaftor will be administered every 12 hours (q12h) from Day 1 through the Week 84 Visit. The ivacaftor dose will be:\n50 mg q12h for subjects 2 to <6 years of age and <14 kg,\n75 mg q12h for subjects 2 to <6  years of age and \u2265 14 kg, or\n150 mg q12h for subjects \u2265 6 years of age."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to provide information regarding the long-term safety and\n      pharmacodynamics of ivacaftor treatment in the pediatric population younger than 6 years of\n      age with Cystic Fibrosis (CF) who have a CFTR gating mutation in at least 1 allele and will\n      further explore the efficacy of long-term ivacaftor treatment in this population of patients\n      with CF."
        }, 
        "brief_title": "Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation", 
        "condition": "Cystic Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Cystic Fibrosis", 
                "Fibrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria (Ivacaftor Arm):\n\n          1. Completed the last study visit of the treatment period of the previous study\n             (NCT01705145)\n\n          2. Hematology, serum chemistry, and vital signs results on Day 1 with no clinically\n             significant abnormalities that would interfere with the study assessments, as judged\n             by the investigator\n\n          3. As judged by the investigator, parent or legal guardian must be able to understand\n             protocol requirements, restrictions, and instructions and the parent or legal\n             guardian should be able to ensure that the subject assents to participation in the\n             study to the degree the subject can assent, and that the subject will comply with and\n             is likely to complete the study as planned\n\n        Inclusion Criteria (Observational Arm):\n\n        1. Subjects who completed their assigned study drug treatment in the previous study\n        (NCT01705145) and elected not to enroll in the ivacaftor arm and subjects who prematurely\n        discontinued treatment in the previous study and received at least 1 dose of study drug\n        treatment in the previous study will be eligible for enrollment in the observational arm.\n\n        Exclusion Criteria (Ivacaftor Arm):\n\n          1. Subjects who prematurely discontinued from the previous study\n\n          2. History of any illness or condition that, in the opinion of the investigator, might\n             confound the results of the study or pose an additional risk in administering study\n             drug to the subject\n\n          3. Subjects with a history of study treatment intolerance as observed in their previous\n             study that, in the opinion of the investigator, might pose an additional risk in\n             administering study drug to the subject\n\n          4. Subjects receiving commercially-available ivacaftor treatment\n\n          5. Subject was unable to complete an adequate slit-lamp examination at the last\n             ophthalmologic examination in the previous study\n\n        Exclusion Criteria: (Observational Arm)\n\n        1. Subjects receiving ivacaftor treatment will not be eligible for enrollment in the\n        observational arm."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "33", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01946412", 
            "org_study_id": "VX11-770-109"
        }, 
        "intervention": {
            "arm_group_label": "Ivacaftor", 
            "intervention_name": "Ivacaftor", 
            "intervention_type": "Drug", 
            "other_name": [
                "VX-770", 
                "Kalydeco"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Cystic Fibrosis", 
        "lastchanged_date": "March 18, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grand Rapids", 
                        "country": "United States", 
                        "state": "Michigan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas city", 
                        "country": "United States", 
                        "state": "Missouri"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edinburgh", 
                        "country": "United Kingdom"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Liverpool", 
                        "country": "United Kingdom"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3, 2-Arm, Roll-Over Study to Evaluate the Long-term Safety and Pharmacodynamics of Ivacaftor Treatment in Pediatric Subjects With Cystic Fibrosis and a CFTR Gating Mutation", 
        "overall_official": {
            "affiliation": "Vertex Pharmaceuticals Incorporated", 
            "last_name": "Yulia Green, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety, as determined by adverse events, clinical laboratory values (serum chemistry and hematology), standard 12-lead electrocardiograms (ECGs), vital signs, and ophthalmologic examinations", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline through week 88"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01946412"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Absolute change from baseline of the previous study in weight", 
                "safety_issue": "No", 
                "time_frame": "Through week 88"
            }, 
            {
                "measure": "Absolute change from baseline in weight", 
                "safety_issue": "No", 
                "time_frame": "Baseline through week 88"
            }, 
            {
                "measure": "Absolute change from baseline of the previous study in stature", 
                "safety_issue": "No", 
                "time_frame": "Through week 88"
            }, 
            {
                "measure": "Absolute change from baseline in stature", 
                "safety_issue": "No", 
                "time_frame": "Baseline through week 88"
            }, 
            {
                "measure": "Absolute change from baseline of the previous study in body mass index (BMI)", 
                "safety_issue": "No", 
                "time_frame": "Through week 88"
            }, 
            {
                "measure": "Absolute change from baseline in BMI", 
                "safety_issue": "No", 
                "time_frame": "Baseline through week 88"
            }, 
            {
                "measure": "Absolute change from baseline of the previous study in sweat chloride", 
                "safety_issue": "No", 
                "time_frame": "Through week 88"
            }, 
            {
                "measure": "Absolute change from baseline in sweat chloride", 
                "safety_issue": "No", 
                "time_frame": "Baseline through week 88"
            }
        ], 
        "source": "Vertex Pharmaceuticals Incorporated", 
        "sponsors": {
            "collaborator": {
                "agency": "Cystic Fibrosis Foundation", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Vertex Pharmaceuticals Incorporated", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}